RE:RE:RE:GLUGYou wont hear about partnerships in any kind of detail they already said that. What they might say is that "we continue to work with partners on things". You will get no details other than that and the revenue for the quarter will not back up that statement at all. What classifies as working with anyway? Does that mean they send a few emails to each other asking questions or does it mean actually paying for Stagezero services? Again doubtful you will ever be told. Pumpers will argue it means tests, bashers will argue it means nothing. Either one could be correct.
All that I see is a lot of more BS that cant be quantified and and easily be manipulated. No facts. No hardcore proof of anything.
LithLover wrote: Really? Becuase I expect we will hear news on partnerships with care groups and at risk work places, new location roll outs, publications/additional data sets:
Continuing through the next twelve months, the Company's focus will be to:
- Drive revenue growth by significantly increasing spend against promotion.
- Position Aristotle + AVRT as the #1 program for early cancer detection for employers with at-risk workforces.
- Fully implement current partnerships with key employer groups using Aristotle + AVRT.
- Present data and analysis with respect to at-risk workforces to demonstrate benefit of Aristotle + AVRT
- Broaden relationships with key oncologists and clinics to enhance the reach of CareOncology/Aristotle with a strong focus on HealthCare Systems in multiple key cities.
- Continue to broaden and deepen Aristotle eg CRC. lung and breast cancer staging.
- Partner and launch in key geographic regions world-wide.
I also see they are participating in the HC Wainwright Global Investment Conference In Person (Sept 12-14, 2022).
frewil11 wrote: I guess we are just waiting for next financing news.